Women’s ovaries are located deep in the pelvic cavity and tumors are difficult to detect at an early stage. About 70% of ovarian cancer patients are found to be in advanced stage with abdominal distension and abdominal mass with ascites. Ideal tumor cytoreduction + chemotherapy is the standard treatment model for ovarian cancer. The so-called ideal tumor cytoreduction is the removal of all visually visible lesions or residual lesions <1 cm, followed by adjuvant chemotherapy. However, due to extensive intra-abdominal metastasis, direct surgery is difficult to achieve ideal tumor cytoreduction. For neoadjuvant chemotherapy, there are differences between Europe and the United States. Europe prefers neoadjuvant chemotherapy + surgery + chemotherapy, while the United States still advocates direct surgery + chemotherapy. In China, on the other hand, a practical treatment plan needs to be developed according to the actual situation of doctors and hospitals. The following is the treatment experience of a patient with advanced ovarian cancer for your reference. A 42-year-old female with abdominal distension for 10 days, on examination: 12*10 cm of irregular masses can be found in the pelvis and nodules can be found in the rectal fossa.PET-CT suggests: hypermetabolic masses in both adnexal areas, perihepatic, paracolic peritoneal and greater omental nodular hypermetabolic masses in both sides, hypermetabolic nodules in the umbilicus, multiple hypermetabolic nodules in the left supraclavicular, right septal, hepatic portal, abdominal aorta and both sides of the iliac vessels.CA125. 2274 U/ml. 2015.3 Laparoscopic exploration was performed (Figure 1 and Figure 2), mass biopsy was performed, pathology: hypofractionated adenocarcinoma. After 2 courses of intravenous chemotherapy with Tysol 180mg + cisplatin 80mg, the ultrasound was repeated: the adnexal mass was significantly reduced, the left ovarian mass was 36*31mm and the right ovarian mass was 29*22mm. CA125 decreased to 41U/ml. 2015.5 Tumor cytoreduction was performed (Figure 3, Figure 4). Intraoperatively, we saw that the peritoneal and pelvic lesions were almost gone, and the operation went very well. Postoperative pathology: infiltration of bilateral ovarian hypofractionated adenocarcinoma, cancer infiltration seen in the greater omentum, 1/27 metastasis in pelvic lymph nodes and 0/10 in the parietal abdominal aorta. Postoperatively, 4 courses of intravenous chemotherapy with Tysol + carboplatin were continued, 6 courses were originally recommended and the patient refused. Now the chemotherapy has been stopped for 6 months and there is no sign of recurrence on review. Follow-up is ongoing. For neoadjuvant chemotherapy in advanced ovarian cancer, although the GOG study has not yet yielded results to improve 5-year survival rates. However, it is still very beneficial for complete surgical resection of the lesion. We will continue to follow up these advanced patients. For patients with advanced ovarian cancer, doctors and family members should not give up lightly and never give up to face the malignant tumor together. Here, we also advise those anxious patients' families to cooperate with doctors' treatment plan and not to rush to operate right away, as comprehensive treatment is needed to prolong the life of advanced patients and reduce their pain.